Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Buy” by Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been assigned an average rating of “Buy” from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $56.82.

A number of brokerages have weighed in on MIRM. Cantor Fitzgerald increased their target price on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Friday, October 11th. Evercore ISI lifted their target price on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Leerink Partners increased their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th.

Mirum Pharmaceuticals Stock Down 1.2 %

Shares of Mirum Pharmaceuticals stock opened at $38.89 on Friday. The company has a debt-to-equity ratio of 1.34, a current ratio of 3.28 and a quick ratio of 3.09. Mirum Pharmaceuticals has a 1-year low of $23.14 and a 1-year high of $45.23. The business has a 50-day moving average of $40.34 and a 200-day moving average of $34.24. The company has a market capitalization of $1.83 billion, a PE ratio of -10.48 and a beta of 1.14.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The business had revenue of $77.90 million during the quarter, compared to analyst estimates of $75.03 million. Mirum Pharmaceuticals had a negative net margin of 40.34% and a negative return on equity of 43.47%. The business’s revenue for the quarter was up 107.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.92) earnings per share. As a group, equities analysts forecast that Mirum Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC grew its holdings in Mirum Pharmaceuticals by 34.2% during the first quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock worth $69,470,000 after acquiring an additional 704,659 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Mirum Pharmaceuticals by 37.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after purchasing an additional 432,824 shares in the last quarter. Clearbridge Investments LLC lifted its stake in Mirum Pharmaceuticals by 165.5% during the second quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after purchasing an additional 436,349 shares during the last quarter. William Blair Investment Management LLC boosted its holdings in Mirum Pharmaceuticals by 8.1% during the second quarter. William Blair Investment Management LLC now owns 677,939 shares of the company’s stock worth $23,179,000 after buying an additional 50,667 shares in the last quarter. Finally, Candriam S.C.A. acquired a new position in Mirum Pharmaceuticals in the second quarter worth approximately $17,384,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.